Predictive value of SUVmax and SUVmean parameters in 18F-PSMA-1007 PET/CT for the diagnosis and disease progression of prostate cancer

doi:10.11958/20250665

Abstract

Abstract:

Objective To explore the predictive value of maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) parameters in ¹⁸F-prostate specific membrane antigen-1007 positron emission tomography/computed tomography (¹⁸F-PSMA-1007 PET/CT) for the diagnosis and disease progression of prostate cancer (PCa). Methods Eighty patients with suspected PCa who underwent ¹⁸F-PSMA-1007 PET/CT examination in the hospital were selected and divided into the PCa group (49 cases) and the non-PCa group (31 cases) according to the biopsy pathological results. The ¹⁸F-PSMA-1007 PET/CT parameters were collected in the two groups of patients at admission, including SUVmax and SUVmean. The prostate specific antigen (PSA) and prostate cancer histological grade (GLEASON) score were also collected in patients of the PCa group at admission and 3 months after admission. The diagnostic efficiency of ¹⁸F-PSMA-1007 PET/CT parameters on PCa was analyzed by receiver operating characteristic (ROC) curve. The correlation between ¹⁸F-PSMA-1007 PET/CT parameters of patients in the PCa group at admission and PSA, GLEASON score was analyzed by Pearson method. Results The SUVmax and SUVmean in the PCa group were higher than those in the non-PCa group (P<0.05). ROC curve analysis showed that the areas under the curves (AUCs) of SUVmax and SUVmean were 0.887 and 0.843 respectively, the sensitivities were 80.65% and 83.87%, and the specificities were 87.76% and 73.47% respectively. The PSA and GLEASON score were lower 3 months after admission than those at admission in the PCa group (P<0.05). Pearson correlation analysis showed that the SUVmax and SUVmean of patients in the PCa group at admission were positively correlated with PSA and GLEASON score at admission and 3 months after admission (P<0.05). Conclusion SUVmax and SUVmean parameters of ¹⁸F-PSMA-1007 PET/CT have high predictive value for the diagnosis and disease progression of PCa.

Key words: prostatic neoplasms, positron emission tomography computed tomography, ¹⁸F-PSMA-1007, diagnosis, SUVmax, SUVmean

CLC Number:

R814.42，R737.25，R445

Figures/Tables 6

References 18

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:10.3322/caac.21660.
[2]	ZHOU J, DING J, QI J. Comparison of typical prostate adenocarcinoma and rare histological variant prostate cancer showed different characteristics and prognosis:A surveillance,epidemiology,and end results database analysis[J]. Eur Urol, 2022, 82(2):152-155. doi:10.1016/j.eururo.2022.02.006.
[3]	胡尘翰, 乔晓梦, 包婕, 等. 前列腺癌局部复发影像报告系统对前列腺癌根治术后局部复发的诊断效能及观察者间评分一致性研究[J]. 中华放射学杂志, 2024, 58(3):293-300.
	HU C H, QIAO X M, BAO J, et al. Diagnostic performance and inter-observer consistency of prostate imaging recurrence reporting system in the detection of local recurrence after radical prostatectomy in patients with prostate cancer[J]. Chin J Radiol, 2024, 58(3):293-300. doi:10.3760/cma.j.cn112149-20231012-00285.
[4]	姜一逸, 刘芙岑, 李波良, 等. ¹⁸F-PSMA-1007与¹⁸F-FDG PET/CT及多参数MRI在前列腺癌诊断中的对比研究[J]. 中华核医学与分子影像杂志, 2024, 44(3):147-152.
	JIANG Y Y, LIU F C, LI B L, et al. Comparative study of ¹⁸F-PSMA-1007,¹⁸F-FDG PET/CT and mpMRI in the diagnosis of prostate cancer[J]. Chin J Nucl Med Mol Imaging, 2024, 44(3):147-152. doi:10.3760/cma.j.cn321828-20230320-00069.
[5]	李艳梅, 李艳, 陈健, 等. 基于¹⁸F-PSMA-1007 PET/CT及临床病理因素预测前列腺癌转移的诊断价值[J]. 放射学实践, 2023, 38(7):925-930.
	LI Y M, LI Y, CHEN J, et al. The diagnostic value of predicting prostate cancer metastasis based on ¹⁸F-PSMA-1007 PET/CT and clinical and pathological factors[J]. Radiol Prac, 2023, 38(7):925-930. doi:10.13609/j.cnki.1000-0313.2023.07.020.
[6]	朱斌, 刘畅, 许晓平, 等. ¹⁸F-PSMA-1007 PET/CT和mpMRI在前列腺癌原发灶检测及病灶腺体内定位的对比研究[J]. 肿瘤影像学, 2023, 32(3):226-236.
	ZHU B, LIU C, XU X P, et al. Comparison of ¹⁸F-PSMA-1007 PET/CT and mpMRI in the detection and intraprostatic localization of primary prostate cancer[J]. Oncoradiology, 2023, 32(3):226-236. doi:10.19732/j.cnki.2096-6210.2023.03.003.
[7]	FOLEY R W, REDMAN S L, GRAHAM R N, et al. Fluorine-18 labelled prostate-specific membrane antigen(PSMA)-1007 positron-emission tomography-computed tomography: normal patterns,pearls,and pitfalls[J]. Clin Radiol, 2020, 75(12):903-913. doi:10.1016/j.crad.2020.06.031.
[8]	钟凯翔, 侯鹏, 吕杰, 等. ¹⁸F-PSMA-1007、⁶⁸Ga-PSMA-11及¹⁸F-FDG PET/CT对初诊可疑前列腺癌的诊断效能比较[J]. 中国医学影像学杂志, 2023, 31(8):865-871.
	ZHONG K X, HOU P, LYU J, et al. Diagnostic performance of ¹⁸F-PSMA-1007,⁶⁸Ga-PSMA-11 and ¹⁸F-FDG PET/CT in newly diagnosed suspicious prostate cancer:a comparative study[J]. Chinese Journal of Medical Imaging, 2023, 31(8):865-871. doi:10.3969/j.issn.1005-5185.2023.08.015.
[9]	丁婷婷, 郝珊瑚, 王治国, 等. ¹⁸F-PSMA-1007 PET/CT与¹⁸F-FDG PET/CT对前列腺癌骨转移的诊断价值比较[J]. 江苏大学学报(医学版), 2023, 33(5):369-373,379.
	DING T T, HAO S H, WANG Z G, et al. Diagnostic value of ¹⁸F-prostate-specific membrane antigen-1007 PET/CT versus ¹⁸F-deoxyglucose PET/CT for bone metastasis in prostate cancer[J]. Journal of Jiangsu University(Medicine Edition), 2023, 33(5):369-373,379. doi:10.13312/j.issn.1671-7783.y230003.
[10]	章明, 马晓芬, 楼云龙, 等. ¹⁸F-PSMA-1007 PET/CT显像可无创精准诊断前列腺癌并确定分期[J]. 分子影像学杂志, 2024, 47(1):1-6.
	ZHANG M, MA X F, LOU Y L, et al. ¹⁸F-PSMA-1007 PET/CT examination can noninvasively diagnose and stage the vast majority of prostate cancer[J]. Journal of Molecular Imaging, 2024, 47(1):1-6. doi:10.12122/j.issn.1674-4500.2024.01.01.
[11]	罗量, 常儒玺, 李运轩, 等. 基于¹⁸F-PSMA-1007 PET/CT影像组学模型在前列腺癌与前列腺增生鉴别诊断中的价值[J]. 中华核医学与分子影像杂志, 2024, 44(2):80-85.
	LUO L, CHANG R X, LI Y X, et al. Value of ¹⁸F-PSMA-1007 PET/CT-based radiomics model for differential diagnosis between prostate cancer and benign prostatic hyperplasia[J]. Chin J Nucl Med Mol Imaging, 2024, 44(2):80-85. doi:10.3760/cma.j.cn321828-20231115-00107.
[12]	SONNI I, FELKER E R, LENIS A T, et al. Head-to-head comparison of ⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection,intraprostatic localization,and determination of local extension of primary prostate cancer:Results from a prospective single-center imaging trial[J]. J Nucl Med, 2022, 63(6):847-854. doi:10.2967/jnumed.121.262398.
[13]	保兰兰, 赵铭, 田蓉蓉, 等. 改良的¹⁸F-PSMA-1007 PET-CT评分与mpMRI PI-RADS评分诊断前列腺癌的效果比较[J]. 肿瘤研究与临床, 2024, 36(9):670-677.
	BAO L L, ZHAO M, TIAN R R, et al. Effect comparison between improved ¹⁸F-PSMA-1007 PET-CT score and mpMRI PI-RADS score for diagnosis of prostate cancer[J]. Cancer Research and Clinic, 2024, 36(9):670-677. doi:10.3760/cma.j.cn115355-20240111-00030.
[14]	LUO L, ZHENG A, CHANG R, et al. Evaluating the value of ¹⁸F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard[J]. Cancer Imaging, 2023, 23(1):108. doi:10.1186/s40644-023-00627-x.
[15]	郑安琪, 王卓楠, 李运轩, 等. ¹⁸F-PSMA-1007 PET/CT对前列腺癌精囊腺侵犯的诊断价值[J]. 中华核医学与分子影像杂志, 2023, 43(9):523-527.
	ZHENG A Q, WANG Z N, LI Y X, et al. Diagnostic value of ¹⁸F-PSMA-1007 PET/CT in seminal vesicle invasion of prostate cancer[J]. Chin J Nucl Med Mol Imaging, 2023, 43(9):523-527. doi:10.3760/cma.j.cn321828-20220505-00140.
[16]	刘伊扬, 毛兴君, 夏佳东. 前列腺小体外泄蛋白联合PSA在PSA“灰区”且PI-RADS评分3分前列腺癌诊断中的临床意义[J]. 中华男科学杂志, 2024, 30(7):597-603.
	LIU Y Y, MAO X J, XIA J D. Clinical significance of prostatic exosomal protein and PSA in detecting prostate cancer with the PSA gray zone and PI-RADS-3 lesions[J]. Natl J Androl, 2024, 30(7):597-603. doi:10.13263/j.cnki.nja.2024.07.003.
[17]	陈丹丹, 楼云龙, 宋丽. ¹⁸F-PSMA-1007 PET/CT应用不同诊断标准对前列腺癌诊断效能的比较[J]. 现代肿瘤医学, 2023, 31(15):2895-2899.
	CHEN D D, LOU Y L, SONG L. Comparison of the diagnostic efficacy of ¹⁸F-PSMA-1007 PET/CT using different diagnostic criteria for prostate cancer[J]. Modern Oncology, 2023, 31(15):2895-2899. doi:10.3969/j.issn.1672-4992.2023.15.024.
[18]	张振华, 付伟, 刘伟良, 等. PET/CT影像组学结合LncRNA-DGCR5在NSCLC精准医疗中的应用研究[J]. 天津医药, 2023, 51(9):1011-1015.
	ZHANG Z H, FU W, LIU W L, et al. Application of PET/CT radiomics combined with LncRNA-DGCR5 in precision medicine of NSCLC[J]. Tianjin Med J, 2023, 51(9):1011-1015. doi:10.11958/20221865.

组别	n	年龄/岁	前列腺体积/mL	家族病史
非PCa组	31	59.87±7.54	38.82±5.61	3（11.9）
PCa组	49	58.86±6.78	39.30±5.76	6（20.5）
χ²或t		0.621	0.367	0.125

组别	n	年龄/岁	前列腺体积/mL	家族病史
非PCa组	31	59.87±7.54	38.82±5.61	3（11.9）
PCa组	49	58.86±6.78	39.30±5.76	6（20.5）
χ²或t		0.621	0.367	0.125

组别	n	SUVmax	SUVmean
非PCa组	31	10.31±2.20	4.63±0.91
PCa组	49	15.44±3.50	6.30±1.33
t		7.291^＊＊	6.135^＊＊

组别	n	SUVmax	SUVmean
非PCa组	31	10.31±2.20	4.63±0.91
PCa组	49	15.44±3.50	6.30±1.33
t		7.291^＊＊	6.135^＊＊

参数	截断值	AUC	95%CI	敏感度/%	特异度/%	约登指数
SUVmax	14.13	0.887	0.797~0.947	80.65	87.76	0.684
SUVmean	5.57	0.843	0.744~0.914	83.87	73.47	0.573

Predictive value of SUVmax and SUVmean parameters in ¹⁸F-PSMA-1007 PET/CT for the diagnosis and disease progression of prostate cancer

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

Figures/Tables 6

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

时间	PSA/（μg/L）	GLEASON评分/分
入院时	24.61±3.14	4.27±0.53
入院3个月后	21.89±3.08	3.71±0.50
t	4.329^＊＊	5.380^＊＊

参数	PSA		GLEASON评分
参数	入院时	入院3个月	入院时	入院3个月
SUVmax	0.439^＊＊	0.387^＊＊	0.388^＊＊	0.367^＊
SUVmean	0.406^＊＊	0.376^＊＊	0.293^＊	0.332^＊

[1]	LI Na, HE Ying, TENG Fei, HE Wenshu, GUO Caifeng, ZHONG Na, WU Qiong, LI Jun. The application value of ultrasound BI-RADS classification combined with serum FGFR1 and GDF3 in the differential diagnosis of benign and malignant breast masses [J]. Tianjin Medical Journal, 2025, 53(3): 247-251.
[2]	JIN Fang, FENG Jing. The rapid pathological diagnostic value of cytological smear in pulmonary nodule during operation [J]. Tianjin Medical Journal, 2024, 52(9): 946-949.
[3]	ZHANG Zhihua, CHANG Taihao, LUO Fei, WANG Yashen, LI Jian. Efficacy and safety of simultaneous prostate biopsy combined with PVP in the treatment of elderly, high-risk and suspected prostate cancer patients [J]. Tianjin Medical Journal, 2024, 52(9): 959-962.
[4]	WANG Lei, MENG Kun, WANG Bing. Analysis of influencing factors of recurrent wheezing in children with bronchopneumonia and construction of prediction model [J]. Tianjin Medical Journal, 2024, 52(8): 850-853.
[5]	JIN Caifeng, WU Wei, WU Ke. Relationship between GBS infection, vaginal microecological changes and adverse pregnancy outcomes of pregnant women [J]. Tianjin Medical Journal, 2024, 52(8): 858-861.
[6]	LI Mengtao, WANG Qian. Connective tissue disease-associated interstitial lung disease: from pathogenesis to "dual-target" treatment strategies [J]. Tianjin Medical Journal, 2024, 52(7): 673-678.
[7]	SHAO Hongxia, WU Juanjuan, YU Hongzhi, WU Qi, WU Junping. Clinical features of hematogenous disseminated pulmonary tuberculosis complicated with intracranial tuberculosis [J]. Tianjin Medical Journal, 2024, 52(5): 495-498.
[8]	FU Xiujuan, LU Zuneng. Research progress of diabetes mellitus complicated with chronic inflammatory demyelinating polyneuropathy [J]. Tianjin Medical Journal, 2024, 52(2): 220-224.
[9]	XIE Haoran, LI Yihao, LIU Cheng, XIA Yuting, QIU Shenglei, XIONG Bin, FENG Qizhen. Research of predictive factors of axillary lymph node metastasis in breast cancer under the context of DIP payment of medical insurance [J]. Tianjin Medical Journal, 2024, 52(11): 1193-1196.
[10]	LU Yibei, JIN Dongxia, SONG Zhenchun, MA Haoyuan, LI Yan, HAO Tianxu, LI Ximing. Preliminary research on clinical application of a new flexible patch ECG [J]. Tianjin Medical Journal, 2024, 52(10): 1095-1099.
[11]	MA Kai, YAO Yibo, WANG Chen. Application value of neutrophil gelatinase associated lipocalin in clinical diagnosis of Crohn's disease [J]. Tianjin Medical Journal, 2024, 52(10): 1116-1120.
[12]	FENG Lianyun, TIAN Jing, WANG Guangxia, LIU Shenjia, WANG Hong, PANG Lina. Value of contrasten hanced ultrasound in the differential diagnosis of renal clear cell carcinoma and urothelial carcinoma [J]. Tianjin Medical Journal, 2023, 51(5): 540-543.
[13]	TENG Lifeng, CHEN Xixi, YE Cong, HUANG Yubing. Expression of serum Sestrin2 in acute ST-segment elevation myocardial infarction and its relationship with ischemia-reperfusion injury [J]. Tianjin Medical Journal, 2023, 51(3): 303-306.
[14]	XU Limin, XIE Yan. Expression and significance of peripheral blood mononuclear cell DNMT1 and serum IL-6 in diabetic nephropathy [J]. Tianjin Medical Journal, 2023, 51(2): 194-197.
[15]	CHEN Jun, ZHENG Jinhao, CHEN Jialiang, CHEN Bo. Detection and clinical significance of serum GGT and CTHRC1 expression levels in patients with Alzheimer's disease [J]. Tianjin Medical Journal, 2023, 51(2): 216-220.